Lunit is implementing its artificial intelligence (AI)-powered breast cancer detection solution, Lunit INSIGHT MMG, as part of Qatar’s national breast cancer screening programme.
Qatar’s Primary Health Care Corporation (PHCC) has integrated Lunit INSIGHT MMG into its Screen for Life programme, the national initiative for breast and bowel cancer screening.
The AI solution aims to improve the early detection of breast cancer, potentially minimising missed diagnoses and enhancing survival rates within Qatar’s triennial screening programme.
The partnership is slated for an initial five-year term. It is said to be the Middle East’s first integration of AI into a nationwide breast screening workflow.
In addition, the AI adoption for national screening collaboration is expected to advance breast cancer screening in Qatar.
Seoul, South Korea-based Lunit said that the implementation has now been initiated following a retrospective validation phase that commenced in March 2023,
The screening process now involves two radiologists who review each mammogram regarding Lunit INSIGHT MMG’s results.
The integration enhances accuracy and efficiency in Qatar’s screening procedures.
Lunit CEO Brandon Suh said: “Our collaboration with Qatar’s PHCC for the ‘Screen for Life’ will equip healthcare providers with a powerful new tool to enhance medical diagnostics.
“As we expand into national screening programs worldwide, we’re enhancing early cancer detection and reshaping preventive care.
“Each implementation brings us closer to our vision of making AI-assisted cancer screening more accurate and accessible to people around the world, regardless of their location.”
Lunit said the collaboration expands its business-to-government (B2G) cancer screening initiatives globally.
In recent times, the AI-powered solutions developer has deployed Lunit INSIGHT MMG in hospitals in Australia, Sweden, the Kingdom of Saudi Arabia, and Iceland.
Lunit INSIGHT MMG is part of the US Food and Drug Administration (FDA)-cleared Lunit INSIGHT suite for cancer screening.
In May, Lunit acquired Volpara Health Technologies, a medical software developer for breast cancer screening.
